BrainStorm Chief Medical Advisor Interviewed on Israel Radio Broadcast; States Stem Cell Therapy Treatment Ready For Clinical Trials

• Press Release
• Source: BrainStorm Cell Therapeutics Inc.
• On 8:00 am EST, Wednesday November 11, 2009

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that its chief medical advisor, Professor Eldad Melamed, was interviewed on November 9, 2009 on Israel’s most popular radio broadcast, Galei Zahal. The interview was conducted by Yaron Willensky, a respected news talk show host, to discuss the latest achievements, treatment and progress of BrainStorm’s stem cell technology and therapy with respect to neurodegenerative diseases such as ALS and Parkinson’s disease.

Related Quotes

Symbol	Price	Change
BCLI.OB	0.29	0.00

{"s" : "bcli.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“The stem cell therapy treatment is ready. We have successfully been able to process autologous adult human mesenchymal stem cells, grow them and differentiate them into other cell types for the treatment of neurodegenerative diseases. We are currently in middle of obtaining approval to begin the first clinical trials on ALS patients in Israel,” stated Professor Melamed during the interview. “Regarding clinical trials for Parkinson’s disease, we are ready to begin,” continued Professor Melamed. “However, we must still complete the regulatory approval process before that can happen.”

“The interview with Professor Eldad Melamed, BrainStorm’s chief medical advisor, on Israeli national radio demonstrates the continuing acceptance of the need for stem cell therapies and recognizes the scientific achievements of BrainStorm and its team,” said Rami Efrati, CEO of BrainStorm.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, former Head of Neurology at Rabin Medical Center, and cell biologist Professor Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The Company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. The Company's current focus is on ALS, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements, including BrainStorm's ability to complete its equity financing transactions previously disclosed. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; minimal working capital and difficulty raising additional capital, dependence on its license to Ramot's technology; ability, together with its licensor, to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.

BrainStorm Cell Therapeutics
Rami Efrati, CEO, +972-3-9236384
efrati@brainstorm-cell.com